Headlands Research Acquires Established Eastern Massachusetts–Based Research Site Specializing in Neurodegenerative Diseases

Headlands Research Eastern Massachusetts deepens the neurology research expertise of the expanding multinational clinical trial site network

San Francisco, CA, April 18, 2023—Headlands Research, a leading multinational network of clinical trial sites, today announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease for over 25 years. 

“With its longstanding focus on memory and movement disorders, Headlands Research Eastern Massachusetts strengthens the breadth and depth of our existing neurology specialty research,” said Cathy Collins, CEO of Headlands Research. “We are proud to welcome Headlands Research Eastern Massachusetts to our expanding network of clinical trial sites, helping to make clinical trials — and the innovative therapies they provide — accessible to more people.” 

Headlands Research Eastern Massachusetts is led by founder and Principal Investigator (PI) Donald Marks, MD, a board-certified neurologist specializing in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders who also currently serves on the staff of the Division of Neurology at Beth Israel Deaconess Hospital – Plymouth. Dr. Marks conducted his first clinical trial in 1993, evaluating tacrine, the first drug approved for the treatment of Alzheimer’s disease, and in 2008, Dr. Marks and his team began research on disease-modifying drugs (DMDs) for Alzheimer’s disease. To date, Dr. Marks and his team have conducted 41 clinical trials, with 36 focusing on Alzheimer’s disease. The team has been in an accelerated growth phase — 13 of the 36 Alzheimer’s disease trials have been started since 2020.  

My team and I are proud of our ability to provide compassionate care for patients and families facing the impact of neurodegenerative diseases. Through our research, we can help fill the gap in the availability of disease-modifying treatments and effective long-term symptomatic therapies,” said Dr. Marks. “Joining Headlands Research increases the number of clinical trials and innovative, investigational treatments available for our patient population.”

By focusing on diversity, quality, and cutting-edge technology, the Headlands Research network of clinical research sites aims to improve people’s lives by advancing innovative medical therapies. Headlands Research also recently announced the launch of Headlands Research Detroit and has plans to continue expanding its network throughout 2023.

To learn more about Headlands Research and its extensive network of research sites, visit https://headlandsresearch.com, contact info@headlandsresearch.com, or follow the company on LinkedIn.

About Headlands Research

Headlands Research is a multinational integrated clinical trial site organization with a mission to improve people’s lives by advancing innovative medical therapies. Its group of exceptional sites focuses on large-volume recruitment of diverse and specialty patient populations while delivering the highest quality data. Headlands Research’s principal investigators are proven industry leaders in their fields with expertise in a wide variety of indications. Utilizing expert recruitment strategies and access to diverse patients through its site databases and physician partnerships, Headlands Research has successfully completed more than 5,000 clinical trials. Additional information about the company is available at www.headlandsresearch.com.

Contact: Brittany Kearns
Phone: 919-270-8054
Email: brittany@crossroadsb2b.com